Company

Cellectar Biosciences, Inc.

Headquarters: Florham Park, NJ, United States

Employees: 12

CEO: Mr. James V. Caruso

NASDAQ: CLRB -0.99%

Market Cap

$33.3 Million

USD as of Jan. 1, 2024

Market Cap History

Cellectar Biosciences, Inc. market capitalization over time

Evolution of Cellectar Biosciences, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Cellectar Biosciences, Inc.

Detailed Description

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Top 1-year algo backtest: +284.14%

$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Cellectar Biosciences, Inc. has the following listings and related stock indices.


Stock: NASDAQ: CLRB wb_incandescent

Stock: FSX: NV4P wb_incandescent

Details

Headquarters:

100 Campus Drive

Florham Park, NJ 07932

United States

Phone: 608 441 8120

Fax: 608 441 8121